En Banc Rehearing Denied Over OxyContin Potency

Law360, New York (May 24, 2010, 2:25 PM EDT) -- A federal appeals court has denied a request for a panel or en banc rehearing of a qui tam suit alleging Purdue Pharma LP overstated the potency of its successful painkiller OxyContin.

No judge requested a poll on the petition for rehearing en banc of the suit filed by former Purdue sales representative Mark Radcliffe, a three-judge panel in the U.S Court of Appeals for the Fourth Circuit said Friday.

Attorney for Radcliffe Mark Tucker Hurt said he was not surprised by the Fourth Circuit's decision...
To view the full article, register now.